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Distinguishing active 
from quiescent disease 
in ANCA‑associated vasculitis 
using attenuated total reflection 
Fourier‑transform infrared 
spectroscopy
Adam D. Morris1*, Camilo L. M. Morais2, Kássio M. G. Lima3, Daniel L. D. Freitas3, 
Mark E. Brady1, Ajay P. Dhaygude1, Anthony W. Rowbottom4,5 & Francis L. Martin6*
The current lack of a reliable biomarker of disease activity in anti‑neutrophil cytoplasmic autoantibody 
(ANCA) associated vasculitis poses a significant clinical unmet need when determining relapsing or 
persisting disease. In this study, we demonstrate for the first time that attenuated total reflection 
Fourier‑transform infrared (ATR‑FTIR) spectroscopy offers a novel and functional candidate biomarker, 
distinguishing active from quiescent disease with a high degree of accuracy. Paired blood and urine 
samples were collected within a single UK centre from patients with active disease, disease remission, 
disease controls and healthy controls. Three key biofluids were evaluated; plasma, serum and urine, 
with subsequent chemometric analysis and blind predictive model validation. Spectrochemical 
interrogation proved plasma to be the most conducive biofluid, with excellent separation between 
the two categories on PC2 direction (AUC 0.901) and 100% sensitivity (F‑score 92.3%) for disease 
remission and 85.7% specificity (F‑score 92.3%) for active disease on blind predictive modelling. 
This was independent of organ system involvement and current ANCA status, with similar findings 
observed on comparative analysis following successful remission‑induction therapy (AUC > 0.9, 100% 
sensitivity for disease remission, F‑score 75%). This promising technique is clinically translatable 
and warrants future larger study with longitudinal data, potentially aiding earlier intervention and 
individualisation of treatment.
Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) characterises an autoimmune 
disorder that results in inflammation and necrosis of small- and medium-sized blood vessels, causing potential 
multi-organ and life threatening disease. Central to its pathogenesis is the activation of primed neutrophils 
through the interaction of ANCA with myeloperoxidase (MPO) and proteinase-3 (PR3) target antigens expressed 
on their cell surface, resulting in neutrophil degranulation, endothelial damage and amplification loop that 
 ensues1–3. Current immunosuppressive treatment strategies are effective with improved patient survival, but 
carry a significant risk of treatment-related toxicity and long-term patient morbidity that often results from the 
sequelae of relapsing disease and required re-exposure to  therapy4–6. The lack of a reliable biomarker of disease 
activity to aid the early detection of relapsing disease represents a significant clinical challenge, risking potentially 
undertreated disease or over exposure to therapy.
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Attenuated total reflection Fourier-transform infrared (ATR-FTIR) biospectroscopy offers a highly versatile, 
non-destructive and cost-effective means of analysing a given biological sample to determine its chemical com-
position; in effect providing a surrogate of its metabolomic profile. Within any sample, the chemical bonds that 
make up its constituent molecules will exhibit a periodic vibrational pattern. Those with a dipole moment are 
active within the infrared (IR) spectral range. ATR-FTIR exploits this by exposing a biological sample to mid-IR 
radiation to provide a spectral pattern based on the degree of IR absorption. As such, it can be used to quanti-
tatively detect biochemical changes caused by pathology and provide a unique spectral fingerprint for disease 
states. Advancements in instrumentation and computational chemometric analysis have enabled ATR-FTIR to 
be applied to a wide range of biofluids and tissue samples, across numerous medical disciplines. Studies have 
employed it to detect disease with a high degree of sensitivity and specificity, including inflammatory arthropathy, 
neurodegenerative disease and  malignancy7–10. Its use in the field of nephrology is emerging with tissue analysis 
of both native and transplanted kidneys to aid current histological assessment and  prognostication11–14, detec-
tion of cast  nephropathy15, renal stone  analysis16,17 and more recently analysis of peritoneal and haemodialysis 
 effluent18,19.
One previous study has applied ATR-FTIR spectroscopy in vasculitis, demonstrating promising results, with 
several characteristic spectral markers identified from urine in a rodent model of crescentic glomerulonephritis 
and patients with renal limited  disease20. This phase one proof-of-concept study aims to determine the potential 
use of ATR-FTIR spectroscopy in AAV as novel biomarker of disease activity, through analysis of a range of 
biofluids and correlation with clinical parameters from patients with multisystem disease.
Results
Study population. One hundred and eight participants are included in the present study; 25 with active 
disease (AD), 38 in disease remission (DR), 10 with membranous nephropathy (MM), five with minimal change 
disease (MCD), 10 with immunoglobulin A nephropathy (IgA), 10 with pre-renal acute kidney injury (AKI) 
in the context of infection and 10 healthy controls (HC). Descriptive baseline characteristics for the active and 
remission disease cohorts are shown in Table 1. AAV participant flow through the study is shown in Supplemen-
tary Information (SI) Fig. S1. Amongst these two groups, overall mean age was 66 ± 11.9 years with no significant 
gender predominance. The majority were Caucasian, with only one South-Asian participant in the remission 
cohort. Baseline characteristics for the disease control groups are outlined in SI Table S1.
Of those with active disease, 16% (n = 4) had undetectable circulating ANCA, 68% (n = 17) had multisystem 
disease and of the remaining 32% (n = 8) with single organ disease, 4 were renal limited, 3 were limited to ear nose 
and throat disease and one had ophthalmic disease. Amongst the remission cohort 52% (n = 20) had persisting 
positive ANCA serology despite clinically quiescent disease. Overall two patients died, both in the AD cohort 
and both due to infection. No patients were lost to follow up. Paired remission samples were attained from 14 
patients in the AD cohort for comparative analysis following successful remission induction therapy. Amongst 
this group the majority (n = 13) were ANCA positive at initial diagnosis, of which six remained ANCA positive 
at the time of paired remission sample collection.
ATR‑FTIR: spectral data and classification models. ATR-FTIR spectrochemical interrogation of 
plasma samples yielded the highest degree of accuracy for discrimination between AD and DR, followed by 
serum and urine sample analysis respectively. Plasma sample data is presented below, with serum and urine 
datasets provided in the SI.
Figures 1a and 1b show the raw and pre-processed IR absorption spectra attained from plasma samples 
between the 900–1800  cm−1 spectral range for participants with AD and DR. Spectra initially appear to overlap. 
Given that a vast majority of constituent biomolecules present in plasma will be common to most individuals, 
this would be expected. Following second order differentiation to resolve overlapping peaks, multivariate analy-
sis using principal component analysis (PCA) exhibits good separation between AD and DR on PC2 direction 
(Fig. 1c). A subsequent supervised classification model using partial least squares discriminant analysis (PLS-
DA) was undertaken (Fig. 1d). In this process 60% of samples with known categories of either AD or DR were 
used as a training set to generate the classification model, with cross validation to prevent overfitting and blind 
assessment of the remaining 40% of samples to test the models predictive performance. The receiver operating 
characteristic (ROC) curve (Fig. 1e) demonstrates excellent ability of ATR-FTIR spectroscopy to distinguish 
between AD and DR using this classification system with an area under the curve of 0.901. This predictive clas-
sification model is shown in Table 2, with 100% sensitivity (F-score 92.3%) for DR and 85.7% specificity (F-score 
92.3%) for correctly identifying AD.
Following successful remission induction therapy, analysis of paired remission samples revealed similar find-
ings with good ability to discriminate AD and DR; PLS-DA AUC > 0.9 (Fig. 2) and 100% sensitivity (F-score 75%) 
for DR on predictive modelling (Table 3). There is a high level of accuracy in distinguishing AD from healthy 
controls (see SI, Fig. S2b,c and Table S2). On PCA scores of HC and DR, there was no clear segregation pattern 
between the two groups on PC2 direction following removal three outlier spectra from the HC cohort (see SI, 
Fig. S2e). Subsequent analysis of all participants in disease remission (n = 52), inclusive of those in remission at 
the time of study enrolment (n = 38) and paired remission samples (n = 14), confirmed excellent separation of 
spectral data from all control groups (see SI, Fig. S3e,f. and Table S3). There was equally good separation of AD 
from all control groups (see SI, Fig. S3b,c and Table S3).
Correlation with clinical parameters. The correlation between ATR-FTIR spectral data for plasma and 
relevant clinical variables amongst those with AD is shown in Table 4. Based on the determination coefficient 
 (R2), other than serum albumin and total protein, there is no demonstrable significant correlation shown and 
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Active Disease (n = 25) Disease Remission (n = 38)
Mean Age (SD) 64 ± 11.9 67 ± 11.9
Sex
Male 12/25 (48%) 20/38 (53%)
Female 13/25 (52%) 18/38 (47%)
Median serum creatinine (μmol/L) 216 (347–132) 122 (174–94)
Mean eGFR (mls/min/1.73m2) 22 (48–8) 47 (65–29)
Newly diagnosed disease 20/25 (80%) –
Relapsing disease 5/25 (20%) –
ANCA serotype
MPO 9/25 (36%) 6/38 (16%)
PR3 12/25 (48%) 14/38 (37%)
Negative 4/25 (16%) 18/38 (47%)
BVAS 16 ± 9.6 0
Organ involvement
Constitutional signs or symptoms 15/25 (60%) –
Mucous membranes/Ophthalmic 6/25 (24%) –
Cutaneous 1/25 (4%) –
ENT 12/25 (48%) –
Respiratory 6/25 (24%) –
Cardiovascular 1/25 (4%) –
Gastrointestinal 0 –
Renal 18/25 (72%) –
Neurological 5/25 (20%) –
Multisystem disease 17/25 (68%) –
Renal limited 4/25 (16%) –
Other laboratory salient laboratory results:
Mean Haemoglobin (g/L) 100 ± 28.3 130 ± 13.4
Mean White cell count  (109/L) 9 ± 3.7 7.2 ± 2.2
Mean Lymphocyte count  (109/L) 1.2 ± 0.7 1.3 ± 0.6
Mean Neutrophil count  (109/L) 7 ± 3.6 5.1 ± 2.2
Mean Platelet count  (109/L) 309 ± 143.5 270 ± 80.6
Median CRP (mg/L) 42 (64.8–4.8) 2.6 (5.3–1.2)
Median ESR (mm/hr) 42 (80.5–9) 12 (19.8–5)
Median ESR (mm/hr) 42 (80.5–9) 12 (19.8–5)
Mean serum albumin (g/L) 34.7 ± 7.3 44.4 ± 2.9
Mean serum total protein (g/L) 62 ± 9.8 67.1 ± 4.7
Co-morbidities
Ischaemic heart disease 1 (4%) 4 (11%)
Congestive cardiac failure 0 1 (3%)
Cerebrovascular disease 1 (4%) 2 (5%)
Hypertension 5 (20%) 18 (47%)
Peripheral vascular disease 0 1(3%)
Diabetes Mellitus 2 (8%) 3 (8%)
Chronic pulmonary disease 6 (24%) 5 (13%)
Chronic liver disease 0 0
Connective tissue disease 1 (4%)* 0
Malignancy 2 (8%)** 1 (3%)***
Immunosuppression
None 8 (26%) 7 (18%)
Prednisolone**** 14 (56%) 15 (39%)
Methylprednisolone 7 (28%) 0
Rituximab within the preceding 6 months 1 (4%) 13 (34%)
Cyclophosphamide 2 (8%) 2 (5%)
Azathioprine 0 6 (16%)
Mycophenolate 0 4 (11%)
Methotrexate 0 1 (3%)
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Table 1.  Characteristics of study population at the time of enrolment. eGFR estimated glomerular filtration 
rate, ANCA anti-neutrophil cytoplasmic autoantibody, MPO myeloperoxidase, PR3 proteinase-3, ESR 
erythrocyte sedimentary rate, CRP C-reactive protein. *One case or rheumatoid arthritis in remission, **One 
case of non-metastatic prostate cancer in remission & one case of colonic tubular adenoma, ***One case 
of non-melanoma skin cancer, **** Amongst the remission cohort a daily dose of prednisolone ≥ 5 mg was 
considered significant.
Figure 1.  ATR-FTIR spectral classification of active disease vs. disease remission for plasma samples—(A) Raw 
spectral data, (B) Pre-processed spectra, (C) PCA scores plot, (D) PLS-DA discriminant function graph, (E) 
ROC curve for PLS-DA, (F) PLS-DA coefficients for identification of spectral biomarkers.
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Table 2.  Classification parameters for plasma samples in active disease (AD) vs. disease remission (DR).
AD vs. DR Accuracy (%) Sensitivity (%) Specificity (%) F-Score (%)
Training (5 LVs) 93.6 96.3 90.9 93.5
Cross-validation 91.7 92.6 90.9 91.7
Test 92.8 100 85.7 92.3
Figure 2.  ATR-FTIR spectral classification of active disease vs. paired remission for plasma samples following 
successful remission induction therapy—(A) Raw spectral data, (B) Pre-processed spectra, (C) PCA scores 
plot, (D) PLS-DA discriminant function graph, (E) ROC curve for PLS-DA, (F) PLS-DA coefficients for 
identification of spectral biomarkers.
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the ability of ATIR-FTIR spectroscopy to accurately discriminate between AD and DR was independent of organ 
system involvement, detectable circulating ANCA, ANCA titre in cases of seropositive disease, renal function, 
commonly used markers of inflammation and other salient laboratory results. There was no significant correla-
tion between spectral data and BVAS, a validated and widely applied clinical assessment tool of disease severity. 
Correlation between ATR-FTIR spectral data for plasma and relevant clinical variables amongst those with DR 
is shown in SI Table S4. This confirmed no significant findings. The sensitivities and specificities provided in 
both tables only relates to the ability to separate the two groups. It was not possible to calculate these respective 
values for age, BVAS ANCA titre and other routine salient laboratory results, as these are variables with defined 
numerical values for which discriminatory algorithms could not be executed.
Treatment data at the time of sample collection is outlined in Table 1. The varied distribution of therapy 
provided the opportunity to tentatively determine the impact of immunosuppression on spectral analysis inde-
pendently of the effects of disease activity. Of the 56% (n = 14) of patients in the AD cohort and 39% (n = 15) in 
the DR cohort on prednisolone, the median daily dose was 40 mg (IQR 60–20) and 5 mg (IQR 10–5) respectively. 
Neither dosing regimens accounted for any difference in data variance (see SI, Figs. S4 and S5). Similarly, rituxi-
mab exposure up to six months prior to sample collection did not influence spectral analysis in the DR cohort (see 
Table 3.  Classification parameters for plasma samples in active disease (AD) vs. paired remission (PR).
AD vs. PR Accuracy (%) Sensitivity (%) Specificity (%) F-Score (%)
Training (2 LVs) 100 100 100 100
Cross-validation 82.6 87.5 77.8 82.4
Test 80.0 100 60.0 75.0
Table 4.  Comparative analysis between clinical variables and ATR-FTIR spectral data from plasma samples. 
ENT ear nose and throat, ANCA anti-neutrophil cytoplasmic autoantibody, MPO myeloperoxidase, PR3 
proteinase-3, BVAS Birmingham vasculitis activity score, eGFR estimated glomerular filtration rate, ESR 
erythrocyte sedimentary rate, CRP C-reactive protein.
Active disease Sensitivity of clinical variable Specificity of clinical variable
Coefficients of determination 
 (R2)
Age – – 0.01
Gender 0.75 0.77 0.29
BVAS – – 0.19
Organ involvement:
Constitutional signs or symptoms 0.60 0.60 0.00
Mucous Membrane/Ophthalmic 0.58 0.50 0.12
Cutaneous 0.83 1.00 0.02
ENT 0.39 0.67 0.14
Respiratory 0.58 0.50 0.02
Cardiovascular 1.00 1.00 0.00
Renal 1.00 0.94 0.52
Neurological 0.50 0.20 0.04
ANCA Positivity 0.67 0.75 0.06
ANCA Serotype
MPO 0.44 0.50 0.00
PR3 0.67 0.38 0.01
Negative 0.75 0.71 0.02
ANCA titre – – 0.12
Serum creatinine (μmol/L) – – 0.27
eGFR(mls/min/1.73m2) – – 0.45
Haemoglobin – – 0.51
White cell count – – 0.51
Lymphocyte count – – 0.24
Neutrophil count – – 0.52
Platelet count – – 0.08
CRP – – 0.18
ESR – – 0.29
Serum albumin – – 0.86
Total protein – – 0.65
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SI, Fig. S6). Meaningful subgroup analysis evaluating the impact of methylprednisolone, cyclophosphamide, aza-
thioprine, methotrexate and mycophenolate were not feasible owing to the limited sample size of each subgroup.
Key spectral biomarkers. Key distinguishing peaks can be identified amongst the spectral data in each 
model based on PLS-DA coefficients. The wavenumber-variables responsible for largest between group differ-
ences provide biomarker extraction through the chemical bond they represent, which in turn can be associated 
with a particular cellular activity. Amongst AD and HC cohorts, wavenumber-variables 1612   cm−1 (adenine 
vibration in DNA) and 1040  cm−1 (symmetric  PO2− stretching in RNA/DNA) were both higher in AD, whereas 
1540  cm−1 (protein Amide II β-sheet) was higher in HC (Fig. 3).
Notable wave-number variables characterising AD from DR and their potential corresponding chemical 
bonds are outlined in Table 5. Noteworthy peaks for AD were in the 1620 – 1716  cm−1 range, representing 
nucleobase functional group expression as the main contributors; 1620  cm−1 (base carbonyl stretching and ring 
breathing mode of nucleic acids), 1698  cm−1  (C2=O guanine), 1701  cm−1 (ν(C=O) thymine) and 1716  cm−1 
(ν(C=O) DNA/RNA). Lipid (1748  cm−1, 1778  cm−1) and protein functional groups at the Amide I (1662  cm−1) 
and Amide II (1481  cm−1) bands were associated with disease remission.
Figure 3.  Main band differences for healthy controls (HC) vs. active disease (AD) using PCA loadings on PC2 
from plasma samples—1612  cm−1 (higher in AD, adenine vibration in DNA), 1540  cm−1 (higher in HC, protein 
Amide II β-sheet), 1040  cm−1 (higher in AD, symmetric  PO2− stretching in RNA/DNA).
Table 5.  Potential spectral biomarkers for distinguishing active disease and disease remission using plasma 
samples based on the PLS-DA coefficients (ν = stretching; δ = bending).
Wavenumber  (cm−1) Tentative assignment Influence on AD
1778 ν(C = C) lipids ↓
1748 ν(C = C) lipids ↓
1716 ν(C = O) DNA/RNA ↑
1701 ν(C = O) thymine ↑
1662 Amide I ↓
1509 In-plane δ(CH) phenyl ring ↑
1481 Amide II ↓
1408 δ(CH3) ↑
1358 ν(C–O), δ(CH), δ(NH) ↑
1230 νas(PO2−) ↓
948 Phosphodiester region (collagen and glycogen) ↑
914 Phosphodiester region (collagen and glycogen) ↑
1698 C2 = O guanine ↑
1654 C = O, C = N, N–H of adenine, thymine, guanine, cytosine ↓
1620 Base carbonyl stretching and ring breathing mode of nucleic acids ↑
1558 Ring base mode ↑
1415 CH deformation ↑
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Discussion
The present study provides the first evidence that ATR-FTIR spectroscopy has the potential to provide an accurate 
biomarker of active disease and treatment response in multisystem AAV. To our knowledge this is the first study 
of its kind, in which we demonstrate its use as a quantitative method to distinguish active from quiescent disease 
with a high degree of sensitivity and specificity from plasma. This was applicable both in renal and extra-renal 
disease irrespective of current ANCA serology.
Given the inherent procedural risks, serial renal biopsies for histological confirmation of active disease is 
not practical and in the context of extra-renal disease, a tissue biopsy is often not feasible and typically has a low 
diagnostic  yield21. Current approaches in clinical practice use two main biomarkers to help predict potential 
relapse; ANCA and B-cell population, however their clinical utility remains limited. Persisting ANCA positivity, 
ANCA reappearance and anti-PR3 associated disease have been associated with a higher rate of  relapse22–25, but 
despite this a significant proportion of de-novo and relapsing disease occurs in the absence of detectable circu-
lating  ANCA26–30, particularly amongst patients with extra-renal  disease31. The significance of rising titres also 
remains  debateable32,33. Moreover, ANCA positivity has been shown to occur in healthy  individuals34–36 as well 
as other systemic  illnesses37, further restricting its use. Similarly, while B-cell repopulation following targeted 
therapy with rituximab has been associated with relapsing  disease22,38,39, follow up data from other large trials 
has not corroborated this  finding33,40 and active disease has been shown to occur with B-cell activity in tissue 
despite depletion in  serum41. Amongst other potential biomarker tools, urinary soluble CD163 (sCD163) and 
urinary monocyte chemoattractant protein-1 (MCP-1) have both demonstrated significant promise, with higher 
levels of both associated with active ANCA-associated  glomerulonephritis42–47. Furthermore, combination of 
the two has yielded a high specificity and positive likelihood ratio for relapsing  disease48. However, any potential 
role of urinary sCD163 and MCP-1 remains limited to renal vasculitis, with a robust non-invasive biomarker of 
multisystem disease still lacking. Other potential biomarkers including novel autoantibodies, autoantigen gene 
expression, serum cytokines and degradation products of the alternative complement pathway have either failed 
to be validated or require further  investigation49.
Biospectroscopy is an innovative candidate for the development of a functional biomarker of disease activity. 
Yu et al.used ATR-FTIR spectroscopy to analyse urine samples from rodent models of inflammatory glomeru-
lonephritis, as well as a limited number of patients with ANCA positive pauci-immune glomerulonephritis 
to determine renal inflammation and  injury20. Several key characteristic spectral markers were identified that 
correlated with the progression and severity of disease. In particular, both the 1545  cm−1 and 1033  cm−1 wave-
number intensity correlated with disease severity in the rodent model, with normalisation to baseline following 
treatment with dexamethasone. However, the 1545  cm−1 band intensity increased with declining renal function 
amongst both patients with active disease and those in remission, failing to discriminate between the two groups. 
The 1545  cm−1 band was also present in the murine model of lupus nephritis, suggesting that it may not be spe-
cific to vasculitis, instead reflecting glomerular inflammation and damage. Nonetheless, these original findings 
demonstrated the potential application of ATR-FTIR spectra from urine as marker of disease activity in patients 
with ANCA positive renal limited disease.
In order to detect differences between patients with active disease and those in clinical remission, we 
employed ATR-FTIR to extract spectral data from three key biofluids; plasma, serum and urine. Using unsu-
pervised learning where spectra are classified without any prior sample knowledge, overall category separation 
using PCA was good in both plasma and serum samples. On subsequent blind predictive modelling of known and 
unknown spectral profiles with PLS-DA, our findings demonstrated that plasma was the most accurate biofluid 
for discriminating between the two categories, correctly identifying active disease in 85.7% of cases and 100% 
of those in remission. This finding was independent of ANCA serology with 16% of patients in the AD cohort 
having undetectable circulating ANCA and 53% of patients having persistent ANCA positivity despite disease 
remission. Parallel findings were also seen in the AD cohort where paired remission samples were attained; 
demonstrating that not only can ATR-FTIR spectroscopy be used as a biomarker of active disease, but it could 
also be applied help determine treatment response. Our results were also applicable to both renal and non-renal 
disease with the majority of patients in the AD cohort having multisystem disease and no demonstrable cor-
relation of discriminating spectral data with organ system involvement. The lack of any significant correlation 
between the spectral data and currently used clinical markers including ANCA, CRP and ESR is unsurprising as 
the latter are all known to have a limited association with disease activity. Similarly, the absence of any significant 
correlation with BVAS suggests that the application of ATR-FTIR spectroscopy may only be used to identify 
active disease and not disease severity. Group separation on PCA plot of spectral data attained from urine may 
have been restricted as not all included patients had renal involvement and of those who did, a urine sample 
could not be attained from three patients.
Several key wavenumber-variables associated with active disease from plasma samples were of particular 
interest, namely 1620  cm−1, 1698  cm−1, 1701  cm−1 and 1716  cm−1 which are all associated increased nucleic acid 
expression. This may reflect the known genetic contribution to disease susceptibility and epigenetic factors of 
disease activity, with reduced DNA methylation of MPO and PRTN3 resulting in increased autoantigen expres-
sion and disease  activity50–52. Alternatively, recognising the role of nuclear extracellular traps (NETs) in disease 
pathogenesis, this this finding may simply reflect increased free cell DNA as a result of NET remnants and 
apoptotic  cells53–56. Protein groups at the Amide I (1662  cm−1) and Amide II (1481  cm−1) bands were associated 
with disease remission. This may be a reflection of plasma protein abundance in the acute phase of illness with 
slightly lower trend in serum albumin observed in active disease (34.7 ± 7.3 g/L) compared to disease remission 
(44.4 ± 2.9 g/L). However, the determination coefficient  (R2) for both serum albumin and total protein did not 
confirm a positive correlation with spectral data amongst the disease remission cohort, but trended towards 
significance in active disease leaving the relevance of this result unclear. Mean serum total protein was largely 
9
Vol.:(0123456789)
Scientific Reports |         (2021) 11:9981  | https://doi.org/10.1038/s41598-021-89344-8
www.nature.com/scientificreports/
similar between the two groups; 62 ± 9.8 g/L vs. 67.1 ± 4.7 g/L. Mass spectrometric analysis could be applied in 
future study to help correlate the ATR-FTIR spectral pattern with potential key compositional properties.
The translation of ATR-FTIR spectroscopy into clinical practice is feasible. Portable handheld devices are cur-
rently in use in non-medical  fields57. Coupled with the integration of chemometric algorithms, minimal sample 
requirements and label free preparation means that ATR-FTIR spectroscopy offers a potential low cost, fast, 
automated near-patient test to complement current clinical practice and help identify patients with active disease. 
Although our results are encouraging they should be considered within the context of its primary limitation; 
despite taking measures to avoid the risk of overfitting, the risk of bias from insufficient training data remains 
a potential factor in this phase one study for biomarker discovery. A larger future phase two validation study 
is required to provide sufficient longitudinal training data and prevent bias from small sample size. Based on 
known outcomes, machine-learning using forward feature extraction algorithms could then be used to construct 
prediction models based on extracted spectral features. Such features would also lend novel insight into evolving 
mechanisms of action. We calculate that the optimal sample size for validation would be 199 samples (79 active 
and 120 remission cases) for a power of 80%. For the optimal sample size we used a Fisher’s exact test considering 
the spectral proportion of active and remission cases, which is roughly 0.4:0.6 (see SI, Figure S15). Given the rare 
nature of disease, such a timely study would be feasible using existing biobanks from previous large randomised 
control trials in the field, with samples from various disease time points alongside current standard diagnostic 
methods. A second limitation to consider is the control groups used in the present study. Although good separa-
tion of active disease from all control groups was seen, other than AKI with systemic infection, disease control 
groups were otherwise restricted to renal limited pathology. Any future study of ATR-FTIR as a biomarker of 
multisystem AAV would benefit from inclusion of controls with other systemic inflammatory conditions, such 
as systemic lupus erythematous or rheumatoid arthritis to help evaluate its clinical utility further.
The absence of a functional biomarker that accurately correlates with disease activity in AAV represents a 
significant clinical need. Our findings demonstrate that ATR-FTIR spectroscopy offers a novel means of distin-
guishing between active disease and remission in multisystem disease, independent of ANCA status. As well as 
aiding diagnosis, this may facilitate early intervention and tailored maintenance therapy to help improve patient 
outcomes, particularly in seronegative disease. These findings require validation in a larger study with longitu-
dinal data and comparison against a wider range of glomerular and autoimmune conditions.
Materials and methods
Patients and ethics. Over a fourteen-month period from February 2019 to March 2020, paired blood and 
urine samples were collected from consecutive patients with active AAV and those in disease remission. The 
active disease cohort consisted of patients with new presentation or relapsing disease. The definition of AAV as 
outlined by the 2012 Chapel Hill Consensus Conference was used. As the histological confirmation of disease 
is often not a viable diagnostic tool in the context of extra-renal disease and a reference standard test with a suf-
ficient degree of sensitivity and specify is lacking in such cases, the index test of ATR-FTIR spectroscopy was 
evaluated in the context of this widely used criterion as reference standard for clinical diagnosis. Patients who 
did not meet this criterion, who were aged < 18 years, unable to provide consent or exhibited dual positivity 
with anti-glomerular basement membrane disease were excluded. Disease remission was defined as a Birming-
ham Vasculitis Activity Score (BVAS) of 0. A significant difference in the spectral data amongst patients with 
and without active AAV was the primary outcome of interest. As this study is applying a novel and previously 
untested technology to this patient group a sample size could not be calculated. All participants were registered 
with the Department of Renal Medicine regional vasculitis service at Lancashire Hospitals NHS Foundation 
Trust, UK. Informed written consent was obtained prior to enrolment in accordance with study approval from 
the Health Research Authority, Cambridge South Research Ethics Committee (REC reference 18/EE/0194) and 
the Research and Development team in the Centre for Health Research and Innovation at Lancashire Teaching 
Hospitals NHS Foundation Trust. All experiments were carried out in accordance with the relevant guidelines 
and regulations.
The following clinical data was collected at baseline assessment; demographics, clinical presentation, BVAS 
and salient laboratory results including current ANCA serotype were applicable, serum creatinine, haemoglobin, 
white cell count, lymphocyte count, neutrophil count, platelet count, C-reactive protein erythrocyte sedimen-
tary rate and urine protein creatinine ratio. Urine samples were sent for microscopy and culture to determine 
the presence of bacteriuria and its potential impact as a confounding factor on ATR-FTIR sample analysis. For 
patients with active disease, further samples were collected following successful remission induction therapy 
where possible for comparative analysis. Control groups including membranous nephropathy, minimal change 
disease, immunoglobulin A nephropathy, acute kidney injury in the context of infection and healthy individuals 
were included for analysis. Participants in the healthy control group were not known to have renal impairment 
and had a normal dipstick urinalysis.
Sample collection and preparation. Samples from participants with active disease were taken in both 
the outpatient clinic and acute in-patient setting. All remission and disease control samples were taken in the 
outpatient clinic. Healthy control samples were attained from individuals working in the hospital outside of the 
laboratory setting. Whole blood samples were collected in EDTA and serum separator tubes. All blood and urine 
samples were centrifuged at 3000 rpm, 4 °C for 10 min. The resulting plasma, serum and supernatant urine were 
collected in 0.5 ml Eppendorf tubes and stored on site at − 80 °C. When required for experimentation samples 
were thawed at room temperature, after which 30 μl aliquots were placed on IR-reflective aluminium coated 
FisherBrand slides and left to air dry for a minimum of 2 h prior to spectroscopic analysis.
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ATR‑FTIR spectral acquisition. ATR-FTIR spectra were attained using a Bruker Tensor 27 FTIR spec-
trometer will Helios ATR attachment (Bruker Optics Ltd, Coventry UK), operated by OPUS 6.5 software. The 
sample area was defined by the diamond crystal internal reflective element, approximately 250 μm by 250 μm. 
Spectra were acquired from 10 locations on each sample; five central and five peripheral to help minimise any 
potential bias. Parameters for spectral acquisition consisted of 32 scans per location, 8  cm−1 spectral resolution 
with 2 × zero-filling and 6 mm aperture setting, yielding a data spacing of 4  cm−1 over 4000–400  cm−1 spectral 
range. The diamond crystal was cleaned with distilled water, dried with Kimwipes and a background absorption 
spectra was taken at the start of each new sample analysis to account for atmospheric conditions.
Spectral pre‑processing. The spectral data were imported into MATLAB R2014b environment (Math-
Works Inc., USA) for pre-processing and subsequent multivariate analysis. Pre-processing consists of math-
ematical techniques employed to the raw spectral data to remove or reduce contributions of signals that are not 
related to the analyte target property or to the sample discrimination, hence, reducing chemically irrelevant 
variations in order to improve the accuracy and precision of qualitative and quantitative  analyses58. Herein, the 
raw spectral data were pre-processed by automatic weighted least squares (AWLS) baseline correction and vec-
tor  normalisation59. Finally, prior to model construction by partial least squares discriminant analysis (PLS-DA), 
the pre-processed data are mean-centred.
Multivariate analysis. Multivariate classification by means of PLS-DA was employed to discriminate the 
spectral data based on the experimental classes. Firstly, the pre-processed data were split into training and test 
(external validation) sets using the MLM  algorithm60. The training set, composed of 60% of the samples, was 
used for model construction, whose optimisation step (defining the number of latent variables (LVs) for PLS-
DA) was performed via venetian blinds cross-validation. The remaining samples (40% of the dataset) assigned 
to the test set were used to evaluate the model classification performance. The spectral replicas per sample were 
averaged prior to model construction so the model was constructed on a sample-basis, hence, with no overlap of 
samples between the training and test sets.
PLS-DA is a well-known chemometric technique of supervised classification. It is based on a linear classifi-
cation model for which the classification criterion is obtained by partial least squares (PLS)61. In PLS-DA, PLS 
is applied to the pre-processed data, reducing them to a few number of LVs, in which the category variables for 
each class in the training set is used to optimise the model. Then, a straight line that divides the classes’ spaces 
is  delineated62. In addition to PLS-DA, prior to supervised classification, the pre-processed data also underwent 
an exploratory analysis by principal component analysis (PCA) in order to identify possible natural clustering 
patterns or trends in the data through the analysis of the 2D PCA scores plots on principal components (PCs) 
1 and  263.
Model validation. Model validation was performed by the calculation of accuracy, sensitivity, specificity 
and F-scores for the test set. The accuracy represents the total number of samples correctly classified, consider-
ing true and false negatives. The sensitivity represents the proportion of positive samples correctly classified, the 
specificity represents the proportion of negative samples correctly classified and the F-score measures the model 
performance considering imbalanced  data64.
Correlation with clinical variables. Correlation between the pre-processed spectra and individual clini-
cal variables was evaluated by PLS regression (for continuous variables) and PLS-DA (for categorical variables). 
PLS and PLS-DA models were built using cross-validation. The association between spectra and a clinical vari-
able was evaluated by assessing the determination coefficient  (R2) and root mean square error of cross-validation 
(RMSECV). Clinical parameters for which the  R2 was low, or RMSECV elevated, were considered to have poor 
correlation with the spectral data.
Data availability
The authors declare that the data supporting the findings of this study are available within the paper and its 
supplementary information. The MATLAB code and instructions on how to process the data are presented in 
previous  publications49–51.
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